Bristol-Myers Squibb Again Named Top Corporation Citizen

Apr 25, 2016 4:05 PM ET

For the eighth consecutive year, Bristol-Myers Squibb ranks in the top 10, ranking sixth of the 100 BestCorporate Citizens, a leading benchmark for socially responsible investors and other stakeholders published by Corporate Responsibility magazine. The company has achieved the No. 1 ranking three times, including 2009, 2012 and 2014. 

The 100 Best Corporate Citizens list ranks companies in the Russell 1000 using nearly 300 data points in seven categories: environment, climate change, employee relations, human rights, governance, finance, and philanthropy. The company rankings have been published since 1999.  

“We are proud to be recognized consistently over the past eight years as a leader in social responsibility, said Carol Powell, global head and vice president of Environment, Health, Safety and Sustainability. “This recognition is a testament to the work we do every day across our company to promote economic, social and environmental sustainability, commitments that are central to our company’s mission and reflect our ongoing commitment to patients, our employees and partners, the environment, and communities around the world.  We take our commitment seriously and extend this expectation to our partners and suppliers as well.”

The company’s Sustainability 2020 goals serve as a plan for making a positive impact in areas relevant to our company and the communities we serve. These goals focus attention on areas of great importance for the future success of our company’s Diversified Specialty BioPharma strategy and for the future health and well-being of the global community. We established our first sustainability goals in 1998.  

Our company’s sustainability efforts go beyond environmental concerns, however. Consistent with our mission to discover, develop and deliver innovative medicines to treat serious diseases such as cancer, cardiovascular disease, fibrotic diseases, genetically defined diseases, hepatitis C, and rheumatoid arthritis, we are also helping to improve health outcomes for patients by partnering to strengthen health care infrastructure, services and education, and by increasing transparency about and access to information on our medicines. 

To learn more about Bristol-Myers Squibb, go to